Trending Articles

FDA advisers back microbiota-based treatment for gut infection

Bio Pharma Dive

Committee members voted in support of Rebiotix’s treatment for recurrent C. diff infections of the intestines, a condition with no regulated options after antibiotics fail

How environmental factors could influence disease and drugs

Pharmaceutical Technology

The study of lifetime exposures, also known as the “exposome”, is providing a new perspective on how environmental and social factors affect disease pathways and general wellbeing, and could influence the way pharma researches drugs.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

Bluebird wins FDA approval of gene therapy for rare brain disorder

Bio Pharma Dive

The therapy, called Skysona and cleared to treat cerebral adrenoleukodystrophy, is the product of more than a decade of work by Bluebird. It will cost $3 million

Novartis dons 'US-first' mindset amid groupwide overhaul, layoffs and generics spinoff

Fierce Pharma

Novartis dons 'US-first' mindset amid groupwide overhaul, layoffs and generics spinoff. Thu, 09/22/2022 - 10:15

90

2022 Research: The Rapid Rise of Ocean Freight Visibility

Download this a benchmark study from FourKites and The Journal of Commerce exploring how international shippers’ usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19.

The future of AI drug discovery & development in immunology and GPCR research

Pharma Phorum

Alphabet subsidiary and precision health company Verily recently announced a breakthrough in its AI drug discovery GPCR research collaboration with Sosei Heptares.

Genome 107

WHO calls for urgent action by countries for achieving Medication Without Harm

The Pharma Data

Encyclopedically, half of all preventable detriment in medical care is drug related, a quarter of which is severe or life- hanging. In the lead up to World Patient Safety Day on 17 September 2022, WHO is emphasizing the global burden of drug detriment.

Drugs 72

More Trending

EMA CHMP recommends authorisation of AstraZeneca’s Evusheld for Covid-19

Pharmaceutical Technology

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation for AstraZeneca ’s Evusheld (formerly AZD7442) for Covid-19 in the European Union (EU).

Intranasal TIPs therapy study shows potential to reduce COVID-19 transmission

Outsourcing Pharma

Gladstone Institutes seek FDA approval for human clinical trial after single-dose, intranasal TIPs treatment for SARS-CoV-2 infection limits transmission in infected animals by decreased viral shedding. Ingredients

Hope for lupus sufferers with Feinstein Institutes-led phase 2 trial

Pharma Phorum

Findings from the litifilimab trial, undertaken by Northwell Health’s Division of Rheumatology and The Feinstein Institutes for Medical Research, have been published in the New England Journal of Medicine and show promise for those who have been diagnosed with systemic lupus erythematosus (SLE).

Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union

The Pharma Data

An Innovative & Creative Problem Solver Approach to Selling in the Medical Device Space

Speaker: Steve Goldstein, Sales Leader

Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.

J&J opens new research hub near San Francisco

Bio Pharma Dive

The roughly 200,000-square-foot facility will house about 400 employees and more than double the size of the drugmaker’s presence in San Francisco

Gilead’s Veklury receives WHO recommendation to treat severe Covid-19

Pharmaceutical Technology

Gilead Sciences has received expanded recommendation under the World Health Organization’s (WHO) Therapeutics and COVID-19: living guideline for the use of Veklury (remdesivir) to treat severe Covid-19 patients.

RNA 87

Pfizer hit with racial discrimination lawsuit over minority fellowship program

Fierce Pharma

Pfizer hit with racial discrimination lawsuit over minority fellowship program. zbecker. Fri, 09/16/2022 - 11:21

100
100

Reconfiguring COVID and influenza vaccines for long-term effectiveness

Pharma Phorum

Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company’s breakthrough vaccine technology, oligoDOM, and how it’s driving the development of new influenza and SARS-CoV-2 vaccines that attack T-cells, providing a long-lasting effect.

Mandatory COVID Vaccination Policy Template

The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.

Biogen and Sage rectifiers Present New Analyses at Psych Congress farther assessing the efficacity and Safety of Zuranolone

The Pharma Data

BiogenInc.( Nasdaq BIIB) and savant rectifiers,Inc.(

AstraZeneca claims positive results for its “add-on” drug for rare blood disease

Bio Pharma Dive

The drug, meant to complement other treatments for paroxysmal nocturnal hemoglobinuria, comes via Alexion, which had acquired it from Achillion in 2019

Drugs 255

FDA approves bluebird bio’s Skysona to treat cerebral adrenoleukodystrophy

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has awarded Accelerated Approval for bluebird bio ’s Skysona (elivaldogene autotemcel; eli-cel) for slowing neurologic dysfunction progression in early, active cerebral adrenoleukodystrophy (CALD) patients.

Biogen nets $592M in Boston real estate sale as cost-cutting campaign rolls on

Fierce Pharma

Biogen nets $592M in Boston real estate sale as cost-cutting campaign rolls on. fkansteiner. Wed, 09/21/2022 - 10:20

Sales 87

NICE says yes to BeiGene’s Brukinsa after Scottish nay

Pharma Phorum

BeiGene’s BTK inhibitor Brukinsa (zanubrutinib) has become the first drug in the class to be recommended for routine NHS use in England and Wales to treat Waldenström macroglobulinaemia (WM) – a rare form of non-Hodgkin lymphoma (NHL).

Drugs 83

FDA Approves Lilly’s Retevmo® (selpercatinib), the First and Only RET Inhibitor for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of Type

The Pharma Data

Tumor-agnostic data supporting approval demonstrated an overall response rate (ORR) of 44% across multiple tumor types.

Vesalius Therapeutics, a buzzy, Flagship-backed startup, cuts jobs six months after public launch

Bio Pharma Dive

When the company debuted in March, it announced plans to hire 200 employees over two years. Now, it’s laid off nearly half its staff in a year when the biotech sector has experienced a sharp market downturn

Merck obtains favourable US court ruling on sitagliptin patent lawsuit

Pharmaceutical Technology

Merck (MSD outside of North America) has reported that it received a ruling in favour of the company from the US District Court for the Northern District of West Virginia in a patent infringement suit against Viatris linked to sitagliptin.

Sales 52

AbbVie and BMS slash 360 jobs in California, the latest in a streak of biopharma layoffs

Fierce Pharma

AbbVie and BMS slash 360 jobs in California, the latest in a streak of biopharma layoffs. fkansteiner. Fri, 09/16/2022 - 13:34

99

Patient centricity is becoming business critical for pharma

Pharma Phorum

New book sets the pharmaceutical industry on a course for bridging the patient centricity optimism gap. Bridging the gulf between patient centricity ambition and reality has never been more important for pharma – luckily, this seemingly insurmountable goal isn’t as far out of reach as many envision.

The New England Journal of Medicine Publishes Pivotal Tofersen Data that Show Benefits in Rare, Genetic Form of ALS

The Pharma Data

Drug developers look at innovative mechanisms to tackle dry eye syndrome

Pharmaceutical Technology

Dry eye syndrome (DES) is an indication whose mainstay treatment has been dominated by Allergan’s Restasis (cyclosporine ophthalmic emulsion 0.05%) ever since its launch in 2003 in the US.

Sanofi, AZ's blockbuster hopeful RSV med nears first approval as showdown with Pfizer, GSK looms

Fierce Pharma

Sanofi, AZ's blockbuster hopeful RSV med nears first approval as showdown with Pfizer, GSK looms. fkansteiner. Fri, 09/16/2022 - 09:36

99

No Walk in the Park: JAMA Editorial Calls for More Park Prosecutions; We Disagree

The FDA Law Blog

By Jeffrey N.

LYNPARZA® (olaparib) Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient (HRD)-Positive Advanced Ovarian Cancer

The Pharma Data

One in two women with advanced ovarian cancer has an HRD-positive tumor.

DNA 52

Optimizing pharmaceutical innovation

Bio Pharma Dive

Elevate pharma product development and marketing through collaboration with physician experts

Rivus raises $132m to advance clinical development of obesity treatment

Pharmaceutical Technology

Rivus Pharmaceuticals has raised $132m in a Series B funding round to clinically advance its lead candidate, HU6, for the treatment of obesity and cardio-metabolic disorders. RA Capital Management led the financing round, which also saw participation from Bain Capital Life Sciences and BB Biotech.

A $3M gene therapy: Bluebird bio breaks its own pricing record with FDA approval of Skysona

Fierce Pharma

A $3M gene therapy: Bluebird bio breaks its own pricing record with FDA approval of Skysona. Mon, 09/19/2022 - 10:21

Keeping the pandemic at bay with needle-free vaccine delivery

Pharma Phorum

COVID-19 is still circulating and there are fears that further spikes in cases are to be expected in the coming months.

WHO strongly advises against antibody treatments for COVID-19 patients

The Pharma Data

The antibody medicines sotrovimab and casirivimab- imdevimab aren’t recommended for cases with COVID- 19, says a WHO Guideline Development Group of transnational experts in The BMJ.